NCT02153489View on ClinicalTrials.gov

A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

Aclidinium bromide

DRUG

Placebo

Trial Locations (2)

22927

Pulmonary Research Institute at the Lung Clinic Grosshansdorf, Großhansdorf

34376

Pneumologische Lehrklinik der Universitätsmedizin Göttingen, Immenhausen

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT02153489 - A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter